TCW stands for: TransCatheter Aortic Valve Implantation and Fractional Flow Reserve-Guided Percutaneous Coronary Intervention versus Conventional Surgical Aortic Valve Replacement and Coronary By-Pass Grafts for Treatment of Patients with Coronary MultiVessel Disease and Aortic Valve Stenosis
The TCW trial aims to investigate whether FFR-guided PCI and TAVI strategy for treatment of MVD and AS will be non-inferior to CABG and SAVR for a composite primary endpoint of all-cause mortality, stroke, myocardial infarction, coronary or valve re-intervention and life-threatening or disabling bleeding at one year.
The trial is a prospective, randomized, controlled, open label, multicenter, international, non-inferiority trial designed to enrol 328 patients in up to 25 centers in Europe (The Netherlands, Germany, Denmark, Hungary, Spain, Greece, Austria and Portugal).
The first patient was included in the Isala hospital in the Netherlands in May 2018.
The principal investigators of the TCW trial are Elvin Kedhi (chairman), MD PhD (interventional cardiologist Isala, Zwolle, The Netherlands) and Thomas Modine (co-chairman), MD PhD (cardiothoracic surgeon CHRU de Lille, Lille, France).